PriceTargets.com logo

Biogen - BIIB Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $179.73
  • Forecasted Upside: -1.24%
  • Number of Analysts: 27
  • Breakdown:
  • 0 Sell Ratings
  • 17 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$181.98 As of 12/4/2025 05:00 PM ET
▲ +1.23 (0.68%)

This chart shows the closing price for BIIB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biogen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIIB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIIB

Analyst Price Target is $179.73
▼ -1.24% Downside Potential
This price target is based on 27 analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $179.73, with a high forecast of $270.00 and a low forecast of $118.00. The average price target represents a -1.24% upside from the last price of $181.98.

This chart shows the closing price for BIIB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 27 contributing investment analysts is to hold stock in Biogen. This rating has held steady since December 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 17 buy ratings
  • 9 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 17 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 15 buy ratings
  • 14 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 17 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 12 buy ratings
  • 20 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 11 buy ratings
  • 21 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 9 buy ratings
  • 19 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 10 buy ratings
  • 17 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 17 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
11/28/2025Jefferies Financial GroupBoost TargetBuy ➝ Buy$190.00 ➝ $210.00
11/25/2025Weiss RatingsUpgradeSell (D+) ➝ Hold (C-)
11/21/2025Piper SandlerReiterated RatingNeutral ➝ Neutral$118.00 ➝ $157.00
11/19/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/13/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
11/7/2025Weiss RatingsDowngradeHold (C-) ➝ Sell (D+)
11/6/2025Stifel NicolausUpgradeHold ➝ Buy$144.00 ➝ $202.00
11/3/2025Tudor PickeringSet Target$157.00
11/3/2025MizuhoBoost TargetOutperform ➝ Outperform$169.00 ➝ $177.00
11/3/2025Sanford C. BernsteinBoost TargetMarket Perform ➝ Market Perform$155.00 ➝ $157.00
10/31/2025Wells Fargo & CompanyBoost Target$140.00 ➝ $155.00
10/31/2025WedbushBoost TargetNeutral ➝ Neutral$135.00 ➝ $143.00
10/31/2025GuggenheimBoost Target$165.00 ➝ $185.00
10/31/2025BMO Capital MarketsBoost Target$128.00 ➝ $150.00
10/31/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$217.00 ➝ $210.00
10/31/2025Robert W. BairdLower Target$255.00 ➝ $250.00
10/24/2025Weiss RatingsUpgradeSell (D+) ➝ Hold (C-)
10/14/2025WedbushBoost TargetNeutral ➝ Neutral$129.00 ➝ $135.00
10/10/2025Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$144.00 ➝ $149.00
10/8/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
10/8/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$219.00 ➝ $217.00
10/6/2025Rothschild & Co RedburnBoost TargetNeutral ➝ Neutral$149.00 ➝ $150.00
9/27/2025Weiss RatingsReiterated RatingSell (D+) ➝ Sell (D+)
9/25/2025Jefferies Financial GroupInitiated CoverageHold ➝ Buy$190.00
9/24/2025CitigroupReiterated RatingNeutral ➝ Neutral
9/24/2025William BlairReiterated RatingOutperform
9/24/2025Needham & Company LLCReiterated RatingHold ➝ Hold
9/12/2025Piper SandlerBoost TargetNeutral ➝ Neutral$115.00 ➝ $118.00
9/4/2025Needham & Company LLCReiterated RatingHold ➝ Hold
8/14/2025Piper SandlerBoost TargetNeutral ➝ Neutral$115.00 ➝ $118.00
8/1/2025CitigroupBoost TargetNeutral ➝ Neutral$125.00 ➝ $135.00
8/1/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$208.00 ➝ $219.00
8/1/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$146.00 ➝ $144.00
8/1/2025HC WainwrightBoost TargetBuy ➝ Buy$187.00 ➝ $194.00
7/21/2025Truist FinancialInitiated CoverageHold$142.00
6/26/2025HC WainwrightReiterated RatingBuy ➝ Buy$187.00
6/25/2025Royal Bank Of CanadaSet TargetOutperform ➝ Outperform$205.00 ➝ $213.00
6/12/2025Piper SandlerReiterated RatingNeutral ➝ Neutral$115.00
6/12/2025WedbushReiterated RatingNeutral ➝ Neutral$121.00
6/12/2025Needham & Company LLCReiterated RatingHold ➝ Hold
5/7/2025MizuhoLower TargetOutperform ➝ Outperform$207.00 ➝ $169.00
5/5/2025JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$185.00 ➝ $175.00
5/2/2025OppenheimerSet Target$205.00
5/2/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$217.00 ➝ $205.00
5/2/2025Canaccord Genuity GroupLower TargetBuy ➝ Buy$265.00 ➝ $220.00
5/2/2025HC WainwrightLower TargetBuy ➝ Buy$241.00 ➝ $187.00
5/2/2025Needham & Company LLCReiterated RatingHold ➝ Hold
5/2/2025Robert W. BairdLower TargetOutperform ➝ Outperform$300.00 ➝ $255.00
4/29/2025Truist FinancialLower TargetBuy ➝ Buy$210.00 ➝ $199.00
4/29/2025Piper SandlerLower TargetNeutral ➝ Neutral$135.00 ➝ $115.00
4/28/2025HSBCDowngradeBuy ➝ Hold$118.00
4/28/2025Hsbc Global ResDowngradeStrong-Buy ➝ Hold
4/25/2025Needham & Company LLCReiterated RatingHold ➝ Hold
4/23/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$219.00 ➝ $197.00
4/22/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$221.00 ➝ $225.00
4/16/2025Needham & Company LLCReiterated RatingHold ➝ Hold
4/9/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$157.00 ➝ $152.00
4/4/2025ArgusDowngradeBuy ➝ Hold
2/18/2025Piper SandlerReiterated RatingNeutral ➝ Neutral$138.00 ➝ $135.00
2/13/2025ScotiabankLower TargetSector Outperform ➝ Sector Outperform$244.00 ➝ $224.00
2/13/2025BMO Capital MarketsLower TargetMarket Perform ➝ Market Perform$156.00 ➝ $139.00
2/13/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$281.00 ➝ $245.00
2/13/2025Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$192.00 ➝ $157.00
2/13/2025CitigroupLower TargetNeutral ➝ Neutral$160.00 ➝ $145.00
2/13/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$231.00 ➝ $225.00
2/13/2025Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$165.00 ➝ $140.00
2/13/2025Truist FinancialLower TargetBuy ➝ Buy$220.00 ➝ $210.00
2/13/2025HC WainwrightLower TargetBuy ➝ Buy$300.00 ➝ $241.00
2/13/2025Needham & Company LLCReiterated RatingHold ➝ Hold
2/13/2025Canaccord Genuity GroupLower TargetBuy ➝ Buy$298.00 ➝ $265.00
2/12/2025CitigroupSet Target$160.00
2/12/2025Needham & Company LLCSet Target$270.00
2/12/2025Wells Fargo & CompanySet Target$165.00
2/11/2025Bank Of America (Bofa)Lower TargetNeutral ➝ Neutral$178.00 ➝ $163.00
2/11/2025Sanford C. BernsteinInitiated CoverageMarket Perform$160.00
1/28/2025CitigroupLower TargetNeutral ➝ Neutral$190.00 ➝ $160.00
1/13/2025William BlairReiterated RatingOutperform
1/10/2025Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$190.00 ➝ $165.00
1/8/2025Truist FinancialLower TargetBuy ➝ Buy$302.00 ➝ $220.00
1/2/2025Piper SandlerDowngradeOverweight ➝ Neutral$315.00 ➝ $138.00
12/20/2024BMO Capital MarketsDowngradeOutperform ➝ Market Perform$230.00 ➝ $164.00
12/16/2024Stifel NicolausDowngradeBuy ➝ Hold$175.00
12/10/2024Bank of AmericaReiterated RatingNeutral$178.00
12/9/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$250.00 ➝ $180.00
11/21/2024MizuhoLower TargetOutperform ➝ Outperform$251.00 ➝ $207.00
11/18/2024Needham & Company LLCDowngradeBuy ➝ Hold$270.00 ➝ $270.00
11/15/2024Wolfe ResearchInitiated CoveragePeer Perform
11/15/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$294.00 ➝ $300.00
11/14/2024CitigroupInitiated CoverageNeutral$190.00
11/13/2024CitigroupUpgradeHold
11/4/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$220.00 ➝ $210.00
10/31/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$190.00 ➝ $180.00
10/31/2024OppenheimerLower TargetOutperform ➝ Outperform$270.00 ➝ $255.00
10/31/2024TD CowenLower TargetBuy ➝ Buy$300.00 ➝ $275.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$300.00 ➝ $300.00
10/31/2024Morgan StanleyDowngradeOverweight ➝ Equal Weight$285.00 ➝ $204.00
10/30/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$270.00 ➝ $270.00
10/17/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$260.00 ➝ $230.00
10/10/2024Raymond James FinancialReiterated RatingMarket Perform
10/4/2024Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$292.00 ➝ $269.00
10/3/2024UBS GroupLower TargetNeutral ➝ Neutral$234.00 ➝ $202.00
9/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$285.00 ➝ $285.00
9/23/2024WedbushLower TargetNeutral ➝ Neutral$210.00 ➝ $205.00
9/19/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$292.00 ➝ $292.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$292.00 ➝ $292.00
9/4/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$285.00 ➝ $285.00
8/19/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$285.00 ➝ $285.00
8/6/2024MizuhoLower TargetOutperform ➝ Outperform$277.00 ➝ $251.00
8/5/2024Truist FinancialReiterated RatingBuy ➝ Buy$340.00 ➝ $302.00
8/2/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$282.00 ➝ $292.00
8/2/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$240.00 ➝ $225.00
8/2/2024ScotiabankLower TargetSector Outperform ➝ Sector Outperform$275.00 ➝ $244.00
8/2/2024WedbushLower TargetNeutral ➝ Neutral$215.00 ➝ $210.00
8/2/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$200.00 ➝ $190.00
8/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$288.00 ➝ $288.00
7/29/2024Robert W. BairdLower TargetOutperform ➝ Outperform$316.00 ➝ $294.00
7/26/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$294.00 ➝ $294.00
7/12/2024Piper SandlerLower TargetOverweight ➝ Overweight$335.00 ➝ $313.00
7/3/2024William BlairReiterated RatingOutperform
6/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$294.00 ➝ $294.00
6/26/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$317.00 ➝ $317.00
6/5/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$317.00 ➝ $317.00
5/29/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$317.00
5/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$300.00 ➝ $300.00
5/22/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$294.00
5/16/2024Truist FinancialReiterated RatingBuy ➝ Buy$340.00 ➝ $340.00
5/3/2024HSBCBoost TargetBuy ➝ Buy$339.00 ➝ $342.00
4/29/2024OppenheimerReiterated RatingOutperform ➝ Outperform$270.00 ➝ $270.00
4/25/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$215.00 ➝ $200.00
4/25/2024WedbushBoost TargetNeutral ➝ Neutral$213.00 ➝ $215.00
4/25/2024HC WainwrightLower TargetBuy ➝ Buy$325.00 ➝ $300.00
4/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$294.00
4/19/2024OppenheimerLower TargetOutperform ➝ Outperform$290.00 ➝ $270.00
4/17/2024UBS GroupLower TargetNeutral ➝ Neutral$250.00 ➝ $214.00
4/17/2024WedbushLower TargetNeutral ➝ Neutral$245.00 ➝ $213.00
4/12/2024Bank of AmericaLower TargetNeutral ➝ Neutral$280.00 ➝ $260.00
4/11/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$270.00 ➝ $240.00
4/4/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$230.00 ➝ $215.00
4/1/2024William BlairReiterated RatingOutperform
3/25/2024Truist FinancialReiterated RatingBuy ➝ Buy$340.00
3/5/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$364.00
2/22/2024MizuhoLower TargetBuy ➝ Buy$355.00 ➝ $277.00
2/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$311.00
2/20/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$310.00 ➝ $305.00
2/16/2024UBS GroupLower TargetNeutral ➝ Neutral$276.00 ➝ $250.00
2/14/2024Robert W. BairdLower TargetOutperform ➝ Outperform$333.00 ➝ $316.00
2/14/2024Piper SandlerLower TargetOverweight ➝ Overweight$350.00 ➝ $325.00
2/14/2024BMO Capital MarketsLower TargetOutperform ➝ Outperform$295.00 ➝ $285.00
2/14/2024OppenheimerLower TargetOutperform ➝ Outperform$295.00 ➝ $290.00
2/14/2024Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$379.00 ➝ $364.00
2/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$325.00
2/14/2024Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$315.00 ➝ $240.00
2/13/2024Needham & Company LLCLower TargetBuy ➝ Buy$305.00 ➝ $300.00
2/12/2024Royal Bank Of CanadaBoost TargetOverweight ➝ Overweight$363.00 ➝ $379.00
2/12/2024Bank Of America (Bofa)Lower TargetNeutral ➝ Neutral$290.00 ➝ $280.00
2/12/2024WedbushBoost TargetNeutral ➝ Neutral$239.00 ➝ $245.00
1/30/2024OppenheimerReiterated RatingOutperform ➝ Outperform$295.00
1/24/2024UBS GroupDowngradeBuy ➝ Neutral$311.00 ➝ $276.00
1/10/2024William BlairReiterated RatingOutperform
1/7/2024BTIG ResearchReiterated RatingNeutral
12/20/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$311.00
12/18/2023OppenheimerBoost TargetOutperform ➝ Outperform$280.00 ➝ $295.00
12/14/2023Stifel NicolausLower TargetBuy ➝ Buy$315.00 ➝ $287.00
12/7/2023Raymond James FinancialUpgradeMarket Perform ➝ Outperform$283.00
11/10/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$361.00 ➝ $373.00
11/9/2023Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$351.00 ➝ $363.00
11/9/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$314.00 ➝ $295.00
11/9/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$343.00 ➝ $365.00
11/9/2023WedbushLower TargetNeutral ➝ Neutral$266.00 ➝ $239.00
11/9/2023William BlairReiterated RatingOutperform
11/8/2023UBS GroupLower TargetBuy ➝ Buy$327.00 ➝ $312.00
10/26/2023William BlairReiterated RatingOutperform
10/26/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$305.00
10/26/2023WedbushLower TargetNeutral ➝ Neutral$270.00 ➝ $266.00
10/11/2023Morgan StanleyLower TargetOverweight ➝ Overweight$381.00 ➝ $361.00
9/6/2023HSBCInitiated CoverageBuy$360.00
9/5/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$363.00 ➝ $381.00
8/29/2023Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$354.00 ➝ $357.00
8/14/2023MizuhoLower TargetBuy ➝ Buy$340.00 ➝ $335.00
8/8/2023Truist FinancialLower TargetBuy ➝ Buy$340.00
8/8/2023BMO Capital MarketsLower TargetOutperform ➝ Outperform$347.00 ➝ $336.00
8/8/2023Atlantic SecuritiesLower TargetNeutral ➝ Neutral$282.00 ➝ $275.00
8/8/2023Needham & Company LLCLower TargetBuy ➝ Buy$323.00 ➝ $305.00
8/8/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$311.00 ➝ $294.00
8/7/2023Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$374.00 ➝ $354.00
8/7/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$350.00 ➝ $343.00
8/7/2023Piper SandlerLower Target$380.00 ➝ $350.00
8/7/2023OppenheimerLower TargetOutperform ➝ Outperform$360.00 ➝ $290.00
8/7/2023Bank of AmericaLower Target$310.00 ➝ $290.00
8/7/2023WedbushLower Target$276.00 ➝ $269.00
8/7/2023Robert W. BairdLower Target$340.00 ➝ $333.00
7/31/2023Royal Bank Of CanadaLower TargetOutperform$379.00 ➝ $374.00
7/27/2023ScotiabankInitiated CoverageSector Outperform$327.00
7/26/2023Royal Bank Of CanadaBoost Target$341.00 ➝ $379.00
7/26/2023Needham & Company LLCBoost TargetBuy ➝ Buy$320.00 ➝ $323.00
7/26/2023Bank of AmericaLower Target$320.00 ➝ $310.00
7/26/2023BMO Capital MarketsLower TargetOutperform$357.00 ➝ $347.00
7/26/2023HC WainwrightReiterated RatingBuy ➝ Buy$325.00
7/25/2023Stifel NicolausLower TargetBuy$324.00 ➝ $320.00
7/25/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$320.00
7/24/2023UBS GroupLower TargetBuy$346.00 ➝ $335.00
7/18/2023BMO Capital MarketsLower Target$380.00 ➝ $357.00
7/11/2023Royal Bank Of CanadaBoost Target$332.00 ➝ $341.00
6/12/2023OppenheimerBoost Target$350.00 ➝ $360.00
6/1/2023Piper SandlerBoost Target$346.00 ➝ $360.00
5/11/2023ArgusBoost Target$320.00 ➝ $350.00
5/4/2023Bank of AmericaBoost Target$300.00 ➝ $320.00
5/3/2023MizuhoBoost Target$315.00 ➝ $340.00
5/1/2023GuggenheimUpgradeNeutral ➝ Buy$270.00 ➝ $350.00
4/26/2023Royal Bank Of CanadaLower Target$344.00 ➝ $340.00
4/26/2023Needham & Company LLCLower Target$325.00 ➝ $321.00
4/26/2023UBS GroupLower Target$347.00 ➝ $346.00
4/26/2023OppenheimerBoost Target$310.00 ➝ $325.00
4/26/2023BarclaysLower Target$307.00 ➝ $302.00
4/25/2023Morgan StanleyBoost Target$349.00 ➝ $371.00
4/21/2023Bank of AmericaBoost TargetNeutral$295.00 ➝ $300.00
4/17/2023WedbushBoost TargetNeutral$249.00 ➝ $263.00
4/17/2023ArgusBoost TargetBuy$315.00 ➝ $320.00
4/17/2023Piper SandlerUpgradeNeutral ➝ Overweight$280.00 ➝ $346.00
4/12/2023Morgan StanleyLower TargetOverweight$351.00 ➝ $349.00
4/12/2023BarclaysLower Target$310.00 ➝ $307.00
4/11/2023Needham & Company LLCReiterated RatingBuy$325.00
3/23/2023HC WainwrightReiterated RatingBuy$325.00
3/13/2023Royal Bank Of CanadaBoost Target$335.00 ➝ $350.00
2/16/2023UBS GroupBoost TargetBuy$337.00 ➝ $340.00
2/16/2023HC WainwrightReiterated RatingBuy$325.00
2/16/2023Royal Bank Of CanadaLower TargetOutperform$359.00 ➝ $333.00
2/16/2023CowenBoost TargetOutperform$300.00 ➝ $315.00
2/16/2023Morgan StanleyBoost TargetOverweight$345.00 ➝ $351.00
2/16/2023OppenheimerLower TargetOutperform$320.00 ➝ $310.00
2/15/2023Needham & Company LLCReiterated RatingBuy$325.00
1/25/2023Needham & Company LLCReiterated RatingBuy$325.00
1/24/2023Morgan StanleyBoost TargetOverweight$325.00 ➝ $345.00
12/1/2022The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$370.00
12/1/2022Atlantic SecuritiesBoost TargetNeutral$220.00 ➝ $295.00
11/30/2022MizuhoInitiated CoverageBuy$325.00
11/30/2022Jefferies Financial GroupBoost TargetBuy$325.00 ➝ $350.00
11/30/2022WedbushBoost TargetNeutral$218.00 ➝ $247.00
11/30/2022BarclaysBoost TargetEqual Weight$275.00 ➝ $313.00
11/15/2022Truist FinancialBoost TargetBuy$265.00 ➝ $350.00
11/14/2022OppenheimerBoost TargetOutperform$300.00 ➝ $315.00
11/11/2022GuggenheimBoost TargetNeutral$265.00 ➝ $270.00
11/1/2022MizuhoBoost TargetBuy$270.00 ➝ $325.00
10/28/2022OppenheimerReiterated RatingOutperform ➝ Outperform$300.00
10/26/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$285.00 ➝ $325.00
10/26/2022CowenBoost Target$270.00 ➝ $300.00
10/26/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$220.00 ➝ $370.00
10/26/2022Morgan StanleyBoost TargetOverweight$321.00 ➝ $325.00
10/26/2022CowenBoost Target$270.00 ➝ $300.00
10/26/2022Royal Bank Of CanadaBoost TargetOutperform$310.00 ➝ $331.00
10/26/2022HC WainwrightBoost TargetBuy$240.00 ➝ $325.00
10/26/2022Atlantic SecuritiesBoost TargetNeutral$200.00 ➝ $220.00
10/26/2022Leerink PartnersBoost TargetOutperform$270.00 ➝ $310.00
10/24/2022Jefferies Financial GroupBoost TargetBuy$300.00 ➝ $325.00
10/13/2022Morgan StanleyBoost TargetOverweight$285.00 ➝ $321.00
10/12/2022Stifel NicolausUpgradeHold ➝ Buy$223.00 ➝ $299.00
10/7/2022ArgusUpgradeHold ➝ Buy$300.00
10/7/2022BarclaysBoost TargetEqual Weight$200.00 ➝ $275.00
10/6/2022UBS GroupBoost TargetBuy$238.00 ➝ $309.00
9/30/2022JPMorgan Chase & Co.Boost TargetNeutral$221.00 ➝ $275.00
9/29/2022OppenheimerBoost Target$230.00 ➝ $300.00
9/28/2022Piper SandlerBoost TargetNeutral$200.00 ➝ $280.00
9/28/2022Royal Bank Of CanadaBoost Target$251.00 ➝ $321.00
9/28/2022Wells Fargo & CompanyBoost TargetOverweight$265.00 ➝ $350.00
9/28/2022WedbushBoost TargetNeutral$183.00 ➝ $217.00
9/28/2022Robert W. BairdUpgradeNeutral ➝ Outperform$224.00 ➝ $340.00
9/28/2022BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$217.00 ➝ $360.00
9/28/2022MizuhoUpgradeNeutral ➝ Buy$207.00 ➝ $270.00
9/22/2022Truist FinancialLower TargetBuy$270.00 ➝ $265.00
9/20/2022Jefferies Financial GroupReiterated RatingBuy ➝ Buy$300.00
9/12/2022Stifel NicolausLower TargetHold$230.00 ➝ $223.00
8/2/2022Robert W. BairdReiterated RatingNeutral ➝ Neutral$224.00
7/22/2022UBS GroupLower Target$238.00
7/22/2022GuggenheimLower Target$190.00
7/22/2022Robert W. BairdReiterated RatingNeutral ➝ Neutral$224.00
7/21/2022CowenLower TargetOutperform$285.00 ➝ $270.00
7/21/2022Truist FinancialLower TargetBuy$320.00 ➝ $270.00
7/21/2022Needham & Company LLCLower TargetBuy$262.00 ➝ $250.00
7/21/2022CowenLower Target$285.00 ➝ $270.00
7/21/2022BarclaysLower TargetEqual Weight$210.00 ➝ $200.00
7/20/2022Royal Bank Of CanadaLower Target$264.00 ➝ $259.00
7/18/2022OppenheimerBoost TargetOutperform$225.00 ➝ $230.00
5/4/2022OppenheimerLower Target$240.00 ➝ $225.00
5/4/2022BarclaysLower Target$219.00 ➝ $210.00
4/28/2022WedbushReiterated RatingNeutral
4/21/2022Leerink PartnersLower TargetOutperform$300.00 ➝ $270.00
4/18/2022Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$235.00 ➝ $265.00
4/12/2022Morgan StanleyLower TargetOverweight$330.00 ➝ $283.00
4/12/2022BarclaysLower TargetEqual Weight$235.00 ➝ $219.00
4/8/2022Needham & Company LLCLower TargetBuy$290.00 ➝ $262.00
4/8/2022OppenheimerLower TargetOutperform$285.00 ➝ $240.00
3/28/2022Bank of AmericaLower TargetNeutral$230.00 ➝ $225.00
3/25/2022OppenheimerReiterated RatingOutperform ➝ Outperform$285.00
3/8/2022Stifel NicolausDowngradeBuy ➝ Hold$304.00 ➝ $223.00
3/3/2022Royal Bank Of CanadaUpgradeSector Perform ➝ Outperform$227.00 ➝ $248.00
2/7/2022Canaccord Genuity GroupLower TargetBuy$335.00 ➝ $305.00
2/4/2022CowenLower TargetOutperform$375.00 ➝ $285.00
2/4/2022Wolfe ResearchLower TargetPeer Perform$244.00 ➝ $217.00
2/4/2022Bank of AmericaLower TargetNeutral$245.00 ➝ $230.00
2/4/2022Needham & Company LLCLower TargetBuy$292.00 ➝ $290.00
2/4/2022Royal Bank Of CanadaBoost TargetSector Perform$225.00 ➝ $227.00
2/4/2022WedbushLower TargetNeutral$195.00 ➝ $185.00
2/4/2022Wells Fargo & CompanyLower TargetEqual Weight$284.00 ➝ $235.00
2/4/2022Morgan StanleyLower TargetOverweight$360.00 ➝ $330.00
2/4/2022OppenheimerLower TargetOutperform$350.00 ➝ $285.00
2/4/2022BarclaysLower TargetEqual Weight$244.00 ➝ $235.00
2/4/2022Robert W. BairdLower TargetNeutral$258.00 ➝ $224.00
2/4/2022BMO Capital MarketsDowngradeOutperform ➝ Market Perform$260.00 ➝ $238.00
2/3/2022Stifel NicolausLower Target$344.00 ➝ $304.00
1/24/2022Leerink PartnersLower TargetOutperform$325.00 ➝ $300.00
1/20/2022BarclaysLower TargetEqual Weight$280.00 ➝ $244.00
1/18/2022Morgan StanleyLower TargetOverweight$363.00 ➝ $360.00
1/18/2022HC WainwrightLower TargetBuy$452.00 ➝ $270.00
1/14/2022Bank of AmericaLower TargetNeutral ➝ Neutral$275.00 ➝ $245.00
1/13/2022GuggenheimDowngradeBuy ➝ Neutral$290.00 ➝ $202.00
1/12/2022MizuhoLower TargetNeutral$270.00 ➝ $207.00
1/12/2022WedbushLower TargetNeutral$249.00 ➝ $195.00
1/12/2022Piper SandlerDowngradeOverweight ➝ Neutral$362.00 ➝ $216.00
1/11/2022Needham & Company LLCLower TargetBuy$386.00 ➝ $328.00
1/10/2022Truist FinancialLower TargetBuy ➝ Buy$502.00 ➝ $343.00
1/6/2022Morgan StanleyLower TargetOverweight$440.00 ➝ $363.00
1/3/2022Robert W. BairdReiterated RatingNeutral ➝ Neutral$258.00
1/3/2022UBS GroupLower Target$390.00 ➝ $335.00
12/30/2021Wells Fargo & CompanyBoost Target$250.00 ➝ $284.00
12/23/2021Bank of AmericaLower TargetNeutral$295.00 ➝ $275.00
12/22/2021Truist FinancialLower TargetReduce ➝ Buy$502.00
12/22/2021OppenheimerLower TargetOutperform$390.00 ➝ $350.00
12/21/2021JPMorgan Chase & Co.Lower TargetNeutral$324.00 ➝ $276.00
12/21/2021Robert W. BairdLower TargetNeutral$296.00 ➝ $258.00
12/20/2021Leerink PartnersLower TargetOutperform$450.00 ➝ $325.00
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$250.00
12/6/2021The Goldman Sachs GroupInitiated CoverageNeutral$271.00
11/19/2021Royal Bank Of CanadaLower TargetSector Perform$295.00 ➝ $277.00
11/18/2021BMO Capital MarketsInitiated CoverageOutperform$315.00
10/28/2021Cantor FitzgeraldLower TargetNeutral$316.00 ➝ $259.00
10/26/2021MizuhoLower TargetNeutral$300.00 ➝ $270.00
10/21/2021HC WainwrightReiterated RatingBuy$453.00
10/21/2021Truist FinancialLower TargetBuy$647.00 ➝ $502.00
10/21/2021Morgan StanleyLower TargetOverweight$447.00 ➝ $440.00
10/21/2021CowenBoost TargetOutperform$375.00 ➝ $450.00
10/21/2021OppenheimerDowngradeOverweight$450.00 ➝ $390.00
10/21/2021Royal Bank Of CanadaLower TargetSector Perform$325.00 ➝ $295.00
10/20/2021Piper SandlerLower TargetOverweight$460.00 ➝ $390.00
10/19/2021Needham & Company LLCInitiated CoverageBuy$400.00 ➝ $399.00
10/18/2021Jefferies Financial GroupReiterated RatingBuy
10/15/2021Stifel NicolausLower TargetBuy$430.00 ➝ $344.00
10/15/2021Cantor FitzgeraldLower TargetNeutral$427.00 ➝ $327.00
10/12/2021Morgan StanleyLower TargetOverweight$455.00 ➝ $447.00
10/8/2021Jefferies Financial GroupLower TargetBuy$500.00 ➝ $400.00
10/8/2021BarclaysLower TargetEqual Weight$395.00 ➝ $290.00
10/5/2021HC WainwrightReiterated RatingBuy$452.00
10/5/2021Leerink PartnersReiterated RatingBuy
9/29/2021Royal Bank Of CanadaLower TargetSector Perform$341.00 ➝ $326.00
9/24/2021Robert W. BairdInitiated CoverageHold$296.00
9/23/2021MizuhoInitiated CoverageHold$300.00
9/23/2021HC WainwrightReiterated RatingBuy$452.00
9/22/2021Needham & Company LLCInitiated CoverageBuy$400.00
9/16/2021UBS GroupBoost TargetPositive ➝ Buy$442.00 ➝ $475.00
9/15/2021Bank of AmericaLower TargetNeutral$400.00 ➝ $360.00
8/2/2021MizuhoBoost TargetNeutral$244.00 ➝ $300.00
7/27/2021Cantor FitzgeraldReiterated RatingNeutral$435.00 ➝ $327.51
7/23/2021Morgan StanleyBoost TargetOverweight$453.00 ➝ $455.00
7/23/2021Royal Bank Of CanadaLower TargetSector Perform$361.00 ➝ $341.00
7/22/2021Stifel NicolausLower TargetAverage ➝ Buy$443.00 ➝ $430.00
7/19/2021Evercore ISISet TargetBuy$324.62
7/16/2021Morgan StanleyLower TargetOverweight$455.00 ➝ $453.00
7/11/2021Robert W. BairdSet TargetHold$358.16
6/28/2021Royal Bank Of CanadaLower TargetSector Perform$400.00 ➝ $354.00
6/18/2021Piper SandlerUpgradeNeutral ➝ Overweight$384.00 ➝ $450.00
6/15/2021Bank of AmericaReiterated RatingBuy$415.00
6/14/2021The Goldman Sachs GroupBoost TargetAverage ➝ Neutral$246.00 ➝ $436.00
6/11/2021Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$500.00
6/10/2021UBS GroupUpgradeNeutral ➝ Buy$463.00
6/10/2021Leerink PartnersBoost TargetOutperform$380.00 ➝ $475.00
6/8/2021William BlairUpgradeMarket Perform ➝ Outperform
6/8/2021Royal Bank Of CanadaBoost TargetSector Perform$259.00 ➝ $400.00
6/8/2021Jefferies Financial GroupBoost TargetBuy$450.00 ➝ $500.00
6/8/2021Morgan StanleyBoost TargetOverweight$343.00 ➝ $455.00
6/8/2021BarclaysBoost TargetEqual Weight$265.00 ➝ $395.00
6/8/2021HC WainwrightBoost TargetBuy$305.00 ➝ $452.00
6/8/2021CitigroupUpgradeSell ➝ Neutral
6/8/2021Atlantic SecuritiesUpgradeUnderweight ➝ Neutral$415.00
6/7/2021Robert W. BairdUpgradeUnderperform ➝ Neutral$216.00 ➝ $382.00
6/7/2021Raymond James FinancialUpgradeUnderperform ➝ Market Perform
6/7/2021CowenUpgradeMarket Perform ➝ Outperform$225.00 ➝ $450.00
6/7/2021Bank of AmericaUpgradeUnderperform ➝ Neutral$235.00 ➝ $400.00
5/18/2021OppenheimerBoost TargetOutperform$300.00 ➝ $325.00
4/23/2021HC WainwrightReiterated RatingBuy
4/19/2021Morgan StanleyLower TargetOverweight$351.00 ➝ $343.00
4/12/2021WedbushBoost TargetNeutral$236.00 ➝ $245.00
2/17/2021Cantor FitzgeraldLower TargetNeutral$278.00 ➝ $268.00
2/5/2021DZ BankDowngradeBuy ➝ Hold$264.00
2/4/2021Credit Suisse GroupLower TargetOutperform$388.00 ➝ $350.00
2/4/2021Leerink PartnersLower TargetPositive ➝ Outperform$430.00 ➝ $380.00
2/4/2021Morgan StanleyLower TargetOverweight$352.00 ➝ $351.00
2/4/2021HC WainwrightBoost TargetBuy$289.00 ➝ $305.00
2/3/2021Piper SandlerLower TargetNeutral$265.00 ➝ $250.00
1/29/2021Stifel NicolausUpgradeHold ➝ Buy$258.00 ➝ $358.00
1/19/2021Morgan StanleyLower TargetOverweight$357.00 ➝ $352.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.12 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 49 very positive mentions
  • 34 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 57 very positive mentions
  • 35 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 76 very positive mentions
  • 56 positive mentions
  • 8 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2025
  • 97 very positive mentions
  • 40 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 97 very positive mentions
  • 40 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Biogen logo
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $181.98
Low: $179.27
High: $182.69

50 Day Range

MA: $157.91
Low: $137.37
High: $181.98

52 Week Range

Now: $181.98
Low: $110.04
High: $185.17

Volume

1,233,937 shs

Average Volume

1,905,301 shs

Market Capitalization

$26.70 billion

P/E Ratio

16.59

Dividend Yield

N/A

Beta

0.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Biogen?

The following Wall Street analysts have issued reports on Biogen in the last twelve months: Argus, Bank Of America (Bofa), Bank of America Corporation, BMO Capital Markets, Canaccord Genuity Group Inc., Citigroup Inc., Guggenheim, HC Wainwright, Hsbc Global Res, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings, Inc., Piper Sandler, Robert W. Baird, Rothschild & Co Redburn, Royal Bank Of Canada, Sanford C. Bernstein, Scotiabank, Stifel Nicolaus, The Goldman Sachs Group, Inc., Truist Financial Corporation, Tudor Pickering, Wall Street Zen, Wedbush, Weiss Ratings, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for BIIB.

What is the current price target for Biogen?

0 Wall Street analysts have set twelve-month price targets for Biogen in the last year. Their average twelve-month price target is $179.73, suggesting a possible downside of 1.2%. Needham & Company LLC has the highest price target set, predicting BIIB will reach $270.00 in the next twelve months. HSBC Holdings plc has the lowest price target set, forecasting a price of $118.00 for Biogen in the next year.
View the latest price targets for BIIB.

What is the current consensus analyst rating for Biogen?

Biogen currently has 17 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BIIB, but not buy more shares or sell existing shares.
View the latest ratings for BIIB.

What other companies compete with Biogen?

Other companies that are similar to Biogen include Amgen, Gilead Sciences, Ionis Pharmaceuticals, Moderna and Prothena. Learn More about companies similar to Biogen.

How do I contact Biogen's investor relations team?

Biogen's physical mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is (617) 679-2000 and its investor relations email address is [email protected]. The official website for Biogen is www.biogen.com. Learn More about contacing Biogen investor relations.